[go: up one dir, main page]

WO2009038110A1 - 神経栄養因子様作用剤 - Google Patents

神経栄養因子様作用剤 Download PDF

Info

Publication number
WO2009038110A1
WO2009038110A1 PCT/JP2008/066812 JP2008066812W WO2009038110A1 WO 2009038110 A1 WO2009038110 A1 WO 2009038110A1 JP 2008066812 W JP2008066812 W JP 2008066812W WO 2009038110 A1 WO2009038110 A1 WO 2009038110A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester
trans
carbon atoms
decenoate
methyl
Prior art date
Application number
PCT/JP2008/066812
Other languages
English (en)
French (fr)
Inventor
Munekazu Iinuma
Shoei Furukawa
Original Assignee
Nagoya Industrial Science Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya Industrial Science Research Institute filed Critical Nagoya Industrial Science Research Institute
Priority to US12/678,671 priority Critical patent/US20100204498A1/en
Priority to JP2009533169A priority patent/JP5447954B2/ja
Priority to EP08831604A priority patent/EP2204172A4/en
Publication of WO2009038110A1 publication Critical patent/WO2009038110A1/ja
Priority to US13/439,058 priority patent/US8557864B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　炭素数8（C8）又は炭素数10（C10）～炭素数12（C12）のいずれかの脂肪酸又はこれらの脂肪酸エステルに包含される、炭素数8(C8)の3,7-ジメチルオクタン酸エチルエステル、ゲラン酸エチルエステル等、炭素数10（C10）のデカン酸メチルエステル、trans-2-デセン酸、trans-2-デセン酸メチルエステル、trans-2-デセン酸エチルエステル、trans-2-デセン酸-2-デセニルエステル、trans-2-デセン酸シクロヘキシルエステル、trans-2-デセン酸イソプロピルエステル、trans-3-デセン酸メチルエステル、trans-9-デセン酸メチルエステル等、炭素数11（C11）のtrans-10-ウンデセン酸メチルエステル、trans-10-ウンデセン酸エチルエステル等、炭素数12（C12）のドデカン酸等のいずれかの化合物、その塩又はそのプロドラッグを有効成分として含有する安全性の高い神経栄養因子様の作用を有する医薬を提供する。
PCT/JP2008/066812 2007-09-19 2008-09-18 神経栄養因子様作用剤 WO2009038110A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/678,671 US20100204498A1 (en) 2007-09-19 2008-09-18 Agent having neurotrophic factor-like activity
JP2009533169A JP5447954B2 (ja) 2007-09-19 2008-09-18 神経栄養因子様作用剤
EP08831604A EP2204172A4 (en) 2007-09-19 2008-09-18 MEDIUM WITH NEUROTROPHIC FACTOR-SUBSTANTIVE EFFECT
US13/439,058 US8557864B2 (en) 2007-09-19 2012-04-04 Agent having neurotrophic factor-like activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-242563 2007-09-19
JP2007242563 2007-09-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/678,671 A-371-Of-International US20100204498A1 (en) 2007-09-19 2008-09-18 Agent having neurotrophic factor-like activity
US13/439,058 Division US8557864B2 (en) 2007-09-19 2012-04-04 Agent having neurotrophic factor-like activity

Publications (1)

Publication Number Publication Date
WO2009038110A1 true WO2009038110A1 (ja) 2009-03-26

Family

ID=40467920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066812 WO2009038110A1 (ja) 2007-09-19 2008-09-18 神経栄養因子様作用剤

Country Status (4)

Country Link
US (2) US20100204498A1 (ja)
EP (2) EP2204172A4 (ja)
JP (1) JP5447954B2 (ja)
WO (1) WO2009038110A1 (ja)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011080982A1 (ja) * 2009-12-28 2011-07-07 日清オイリオグループ株式会社 うつ病又はうつ状態の予防又は治療用油脂組成物
WO2012060396A1 (ja) 2010-11-02 2012-05-10 財団法人名古屋産業科学研究所 トランス－２－デセン酸誘導体及びこれを含有する医薬
EP2484358A1 (en) * 2009-09-30 2012-08-08 The Nisshin OilliO Group, Ltd. Agent for inhibiting decrease of visceral fat in patient with parkinson's disease
WO2012105476A1 (ja) 2011-01-31 2012-08-09 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
WO2012105477A1 (ja) 2011-01-31 2012-08-09 日本臓器製薬株式会社 鎮痛剤
WO2013146437A1 (ja) * 2012-03-26 2013-10-03 シーシーアイ株式会社 ３－デセン酸誘導体およびその用途
WO2013161994A1 (ja) 2012-04-27 2013-10-31 日本臓器製薬株式会社 鎮痛剤
WO2013161993A1 (ja) 2012-04-27 2013-10-31 日本臓器製薬株式会社 トランス-2-デセン酸誘導体及びこれを含有する医薬
JP2013241408A (ja) * 2012-04-27 2013-12-05 Nagoya Industrial Science Research Institute トランス−２−デセン酸誘導体を含有する医薬
WO2014142276A1 (ja) * 2013-03-15 2014-09-18 岐阜市 ４－ハイドロパーオキシ－トランス－２－デセン酸誘導体及びこれを含有する医薬
WO2016044000A1 (en) * 2014-09-15 2016-03-24 Elevance Renewable Sciences, Inc. Low-toxicity olefinic ester compositions and methods of using the same
WO2017141911A1 (ja) * 2016-02-15 2017-08-24 小野薬品工業株式会社 ヘキサデセン酸誘導体
JP2021107394A (ja) * 2012-06-15 2021-07-29 ヴィタフロ （インターナショナル） リミテッドＶｉｔａｆｌｏ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） Ｌｔｄ 栄養製品
JP2023018063A (ja) * 2017-04-10 2023-02-07 ヴィタフロ （インターナショナル） リミテッド てんかんの治療に使用するための組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020133D0 (en) * 2010-11-26 2011-01-12 Royal Holloway & Bedford New College Therapeutic use of compounds
BR112014011769A2 (pt) 2011-11-16 2017-05-09 Technix Ind Ltd agentes de redução de betume
WO2015184509A1 (en) 2014-06-06 2015-12-10 Deakin University Methods of treating neurodevelopmental diseases and disorders
CN107427485B (zh) 2015-02-20 2021-06-18 雀巢产品有限公司 用于治疗焦虑症的中链脂肪酸及其甘油三酯
US11535774B2 (en) 2021-03-08 2022-12-27 Technix EnviroCutter IP Limited Bitumen cutback compositions and methods of use thereof
CN118976017A (zh) * 2024-08-02 2024-11-19 南京邮电大学 中碳链烯酸及其衍生物在制备促进血管再生和神经功能恢复药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316092A (ja) 1993-06-01 1995-12-05 Ono Pharmaceut Co Ltd ペンタン酸誘導体、その製造方法およびそれらを含有する薬剤
JP2000007568A (ja) 1998-04-23 2000-01-11 Takeda Chem Ind Ltd 神経栄養因子様作用剤
JP2002080467A (ja) 1999-08-25 2002-03-19 Takeda Chem Ind Ltd ニューロトロフィン産生・分泌促進剤
JP2003113085A (ja) 1998-04-23 2003-04-18 Takeda Chem Ind Ltd 神経栄養因子様作用剤
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
WO2003084542A1 (fr) 2002-04-10 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Accelerateur de production d'un facteur neurotrophique
WO2005032535A1 (ja) 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. 神経再生促進剤
JP2007217311A (ja) * 2006-02-14 2007-08-30 Okayama Univ 神経細胞分化誘導剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2496270A (en) * 1946-02-09 1950-02-07 Synergistics Inc Skin dressings with fugitive colors
JPS58135878A (ja) * 1981-09-22 1983-08-12 Suntory Ltd 新規アイラントン誘導体及びその製造法
US4560785A (en) 1983-03-02 1985-12-24 Ss Pharmaceutical Co., Ltd. Phenylacetic ester derivatives and process for preparing the same
JPS59161331A (ja) * 1983-03-02 1984-09-12 Ss Pharmaceut Co Ltd 新規なフェニル酢酸エステル誘導体
JPH07173166A (ja) * 1993-11-05 1995-07-11 Takeda Chem Ind Ltd Ｔａｎ−１６０７ａ誘導体、その製造法および用途
JP3337615B2 (ja) * 1997-03-03 2002-10-21 花王株式会社 アルコールの製造方法
US6652866B1 (en) * 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
AU1289899A (en) 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
CN1187364C (zh) 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
CA2378557C (en) * 1999-08-05 2009-12-08 Tamara Stipcevic Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration
WO2002062302A2 (en) 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
CA2439118A1 (en) * 2001-02-26 2002-09-06 Yujun Li Composition for aroma delivery with improved stability and reduced foaming
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2002090375A2 (en) 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
FR2894577B1 (fr) * 2005-12-14 2008-02-22 Fabre Pierre Dermo Cosmetique Nouveaux composes polyinsatures, leur procede de preparation et les compositions les contenant.
WO2009102443A2 (en) * 2008-02-15 2009-08-20 The Government Of The Usa, As Represented By The Secretary Of The Dept. Of Health & Human Services; Octanoic acid formulations and methods of treatment using the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316092A (ja) 1993-06-01 1995-12-05 Ono Pharmaceut Co Ltd ペンタン酸誘導体、その製造方法およびそれらを含有する薬剤
JP2000007568A (ja) 1998-04-23 2000-01-11 Takeda Chem Ind Ltd 神経栄養因子様作用剤
JP2003113085A (ja) 1998-04-23 2003-04-18 Takeda Chem Ind Ltd 神経栄養因子様作用剤
JP2002080467A (ja) 1999-08-25 2002-03-19 Takeda Chem Ind Ltd ニューロトロフィン産生・分泌促進剤
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
WO2003084542A1 (fr) 2002-04-10 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Accelerateur de production d'un facteur neurotrophique
WO2005032535A1 (ja) 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. 神経再生促進剤
JP2007217311A (ja) * 2006-02-14 2007-08-30 Okayama Univ 神経細胞分化誘導剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANN NEUROL., vol. 51, no. 1, January 2002 (2002-01-01), pages 133 - 6
ARVANOV, V.L. ET AL.: "The effects of short- chain fatty acids on the neuronal membrane functions of Helix pomatia. II. Cholinoreceptive properties", CELL MOL NEUROBIOL, vol. 6, no. 2, 1986, pages 165 - 75 *
BIOL PSYCHIATRY, vol. 61, 2007, pages 661 - 670
BR J PSYCHIATRY., vol. 189, October 2006 (2006-10-01), pages 317 - 23
HORIE, H. ET AL.: "Cell membrane expansion and blockade of action potentials produced by 2-decenoic acid in cultured dorsal root ganglion neurons", BRAIN RES, vol. 411, no. 2, 1987, pages 298 - 303, XP026860901 *
J NEURAL TRANSM., vol. 112, no. 5, May 2005 (2005-05-01), pages 703 - 11
J NEUROSCI., vol. 27, no. 16, 18 April 2007 (2007-04-18), pages 4424 - 34
NEUROPSYCHOPHARMACOLOGY, vol. 28, no. 2, February 2003 (2003-02-01), pages 397 - 401
PSYCHOPHARMACOLOGY, vol. 180, no. 1, June 2005 (2005-06-01), pages 95 - 9
See also references of EP2204172A4
SULEYMANIAN, M.A. ET AL.: "The effects of short- chain fatty acids on the neuronal membrane functions of Helix pomatia. I. Electrical properties", CELL MOL NEUROBIOL, vol. 6, no. 2, 1986, pages 151 - 63, XP008132710 *
TAKENAKA, T. ET AL.: "Effects of fatty acids on membrane currents in the squid giant axon", J MEMBR BIOL, vol. 95, no. 2, 1987, pages 113 - 20, XP009137573 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649288B2 (en) 2009-09-30 2017-05-16 The Nisshin Oillio Group, Ltd. Inhibitor of visceral fat loss in Parkinson's disease patients
EP2484358A1 (en) * 2009-09-30 2012-08-08 The Nisshin OilliO Group, Ltd. Agent for inhibiting decrease of visceral fat in patient with parkinson's disease
EP2484358A4 (en) * 2009-09-30 2014-10-15 Nisshin Oillio Group Ltd MEANS OF INHIBITING THE REMOVAL OF VISCERAL FAT IN PATIENTS WITH MORBUS PARKINSON
WO2011080982A1 (ja) * 2009-12-28 2011-07-07 日清オイリオグループ株式会社 うつ病又はうつ状態の予防又は治療用油脂組成物
WO2012060396A1 (ja) 2010-11-02 2012-05-10 財団法人名古屋産業科学研究所 トランス－２－デセン酸誘導体及びこれを含有する医薬
US8987486B2 (en) 2010-11-02 2015-03-24 Nagoya Industrial Science Research Institute Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
CN103338761A (zh) * 2011-01-31 2013-10-02 日本脏器制药株式会社 抗癌剂所引起的周围神经病的预防或治疗剂
JP5009450B1 (ja) * 2011-01-31 2012-08-22 日本臓器製薬株式会社 鎮痛剤
WO2012105477A1 (ja) 2011-01-31 2012-08-09 日本臓器製薬株式会社 鎮痛剤
WO2012105476A1 (ja) 2011-01-31 2012-08-09 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
JPWO2013146437A1 (ja) * 2012-03-26 2015-12-10 飯沼　宗和 ３−デセン酸誘導体およびその用途
WO2013146437A1 (ja) * 2012-03-26 2013-10-03 シーシーアイ株式会社 ３－デセン酸誘導体およびその用途
WO2013161994A1 (ja) 2012-04-27 2013-10-31 日本臓器製薬株式会社 鎮痛剤
WO2013161993A1 (ja) 2012-04-27 2013-10-31 日本臓器製薬株式会社 トランス-2-デセン酸誘導体及びこれを含有する医薬
JP2013241408A (ja) * 2012-04-27 2013-12-05 Nagoya Industrial Science Research Institute トランス−２−デセン酸誘導体を含有する医薬
US9428477B2 (en) 2012-04-27 2016-08-30 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
JP2021107394A (ja) * 2012-06-15 2021-07-29 ヴィタフロ （インターナショナル） リミテッドＶｉｔａｆｌｏ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） Ｌｔｄ 栄養製品
WO2014142276A1 (ja) * 2013-03-15 2014-09-18 岐阜市 ４－ハイドロパーオキシ－トランス－２－デセン酸誘導体及びこれを含有する医薬
JPWO2014142276A1 (ja) * 2013-03-15 2017-02-16 アピ株式会社 ４−ハイドロパーオキシ−トランス−２−デセン酸誘導体及びこれを含有する医薬
WO2016044000A1 (en) * 2014-09-15 2016-03-24 Elevance Renewable Sciences, Inc. Low-toxicity olefinic ester compositions and methods of using the same
JPWO2017141911A1 (ja) * 2016-02-15 2018-12-06 小野薬品工業株式会社 ヘキサデセン酸誘導体
WO2017141911A1 (ja) * 2016-02-15 2017-08-24 小野薬品工業株式会社 ヘキサデセン酸誘導体
JP2023018063A (ja) * 2017-04-10 2023-02-07 ヴィタフロ （インターナショナル） リミテッド てんかんの治療に使用するための組成物
JP7491491B2 (ja) 2017-04-10 2024-05-28 ヴィタフロ （インターナショナル） リミテッド てんかんの治療に使用するための組成物

Also Published As

Publication number Publication date
EP2457567A1 (en) 2012-05-30
US20100204498A1 (en) 2010-08-12
US20120264959A1 (en) 2012-10-18
EP2457567B1 (en) 2015-12-30
JPWO2009038110A1 (ja) 2011-01-06
EP2204172A4 (en) 2010-09-22
JP5447954B2 (ja) 2014-03-19
EP2204172A1 (en) 2010-07-07
US8557864B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
WO2009038110A1 (ja) 神経栄養因子様作用剤
PH12017501328B1 (en) Self-emulsifying composition of ?-3 fatty acid
WO2006099358A3 (en) Antimicrobial compositions comprising esters of hydroxycarboxylic acids
WO2005079797A3 (en) Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
WO2008100977A3 (en) Carbamates therapeutic release agents as amidase inhibitors
MX2009004246A (es) Composiciones antimicrobianas.
WO2003013497A1 (fr) Compositions s'averant efficaces pour prevenir ou soulager des troubles ou maladies provoques par une hypofonction cerebrale
WO2009150022A3 (de) Verfahren zur herstellung von sphingolipiden durch enzymatische n-acylierung von lysosphingolipiden unter verwendung einer pilz-lipase und eines fettsäurealkylesters
WO2014005013A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MX2009009472A (es) Formulaciones herbicidas liquidas de sulfonilurea.
IL142535A0 (en) Pharmaceutical compositions for the treatment of inflammation
WO2010000744A3 (en) Use of cationic surfactants as sporicidal agents
EP4233838A3 (en) Pharmaceutical formulations containing corticosteroids for topical administration
WO2007079180A3 (en) Inhibitors of fatty acid amide hydrolase
WO2008115069A3 (en) Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents
WO2009051632A3 (en) Physiological coolants based on lactoyl esters of menthyl lactate
WO2009150023A3 (de) Verfähren zur herstellung von sphingolipiden durch enzymatische n-acylierung von lysosphingolipiden unter verwendung einer lipase und eines fettsäureglycerinesters
GR1006803B (el) Παρασιτοκτονος συνθεση
NZ601001A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
SI1718679T1 (sl) Estri hialuronske kisline z rheinom, postopek za njihovo pripravo in sestavki, ki omenjene vsebujejo
EP2327398A3 (en) Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
WO2010010958A3 (en) Pesticidal composition
WO2009134375A3 (en) Novel pyriproxyfen compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831604

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009533169

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12678671

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008831604

Country of ref document: EP